HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PACB
Pacific Biosciences of California, Inc.
PACB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PACB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
PACB's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PACB PE Valuation
PACB has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PACB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect PACB's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
PACB has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus PACB down 127%.
PACB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$1.46 | -$0.19 |
| Q2 2024 | -$1.50 | -$0.15 |
| Q1 2024 | -$1.14 | +$0.25 |
| Q4 2023 | -$1.21 | +$0.19 |
| Q3 2023 | -$1.27 | +$0.07 |
| Q2 2023 | -$1.35 | -$0.43 |
| Q1 2023 | -$1.39 | -$0.58 |
| Q4 2022 | -$1.40 | -$0.51 |
PACB lost $0.40 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PACB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over PACB on profitability, with a higher operating margin.
PACB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40.6M | +5.5% |
| Q2 2026 | $39M | -1.9% |
| Q1 2026 | $37.2M | +0.1% |
| Q4 2025 | $44.6M | +14% |
| Q3 2025 | $38.4M | -3.8% |
| Q2 2025 | $39.8M | +10% |
| Q1 2025 | $37.2M | -4.3% |
| Q4 2024 | $39.2M | -33% |
PACB's revenue is recovering but still below its 2023 peak: $41M last quarter, up 5.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -91% | +9.9 points |
| Q2 2026 | -114% | -1.6 points |
| Q1 2026 | -22% | +1132 points |
| Q4 2025 | -92% | +298 points |
| Q3 2025 | -101% | +59 points |
| Q2 2025 | -113% | +376 points |
| Q1 2025 | -1155% | -945 points |
| Q4 2024 | -390% | -240 points |
PACB's operating margin was −91% last quarter, up 9.9 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PACB on cash generation, producing positive trailing cash flow while its opponent burns cash.
PACB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$38.6M | -$20M |
| Q2 2026 | -$37.1M | -$7.2M |
| Q1 2026 | -$47.7M | -$2.3M |
| Q4 2025 | -$19.9M | +$12.3M |
| Q3 2025 | -$18.6M | +$26.1M |
| Q2 2025 | -$29.9M | +$25.8M |
| Q1 2025 | -$45.4M | +$34.1M |
| Q4 2024 | -$32.3M | +$27.3M |
PACB has burned cash in almost every quarter: −$143M over the past year, against −$126M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PACB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PACB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +592K shares |
| 1 year | +3.5% | +10.4M shares |
| 3 years | +22% | +56.2M shares |
| 5 years | +45% | +96.1M shares |
| Available history | +100% | +155M shares |
PACB has 311M diluted shares, up 3.5% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PACB Net Leverage
PACB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PACB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 50.9 | Neutral |
PACB's weekly RSI is 53 (neutral) and its Stochastic is 51 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PACB PE vs Healthcare Sector
| Metric | PACB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PACB has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PACB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.15 | 8.4% below |
| 20 week MA | $1.69 | 17% above |
| 50 week MA | $1.67 | 18% above |
| 100 week MA | $1.57 | 25% above |
| 200 week MA | $4.13 | 52% below |
PACB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PACB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.24 | $27.1 | +418% |
| 2021 | $27.1 | $21.4 | -21% |
| 2022 | $21.4 | $8.49 | -60% |
| 2023 | $8.49 | $9.81 | +16% |
| 2024 | $9.81 | $1.86 | -81% |
| 2025 | $1.86 | $1.77 | -4.8% |
| 2026 YTD | $1.77 | $1.97 | +11% |
PACB has the edge over HIMS on returns for 2026, with the stronger performance.